No correlation was found between NA BA2 titers following the fourth dose and age, sex, comorbidities (diabetes mellitus, hypertension, dyslipidemia, and impaired renal function), or subtypes of immunosuppression treatment (MMF, mTOR, or prednisone). This evidence concerns the gene CD9 and metabolic syndrome.